Conference Summaries

Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

The Body Covers: The 52nd Annual Meeting of the American Association for the Study of Liver Diseases

Analysis of 40KDA Peginterferon Alfa-2a (Pegasys) in Combination with Ribavirin, Mycophenolate Mofetil, Amantadine or Amantadine Plus Ribavirin in Patients That Relapsed or Did Not Respond to Rebetron Therapy: A Report of Two Randomized Mulitcenter Efficacy and Safety Studies
Coverage by Jorge L. Herrera, M.D.
Treatment with 40KDA Peginterferon Alfa-2a (Pegasys) in Combination with Ribavirin Significantly Enhances Quality of Life Compared with Interferon Alfa-2b Plus Ribavirin
Coverage by Jorge L. Herrera, M.D.
The Clinical Significance of Hepatitis C Virus (HCV) In Human Immunodeficiency Virus (HIV) Co-Infection
Coverage by Jorge L. Herrera, M.D.
Effect of HAART on Liver-Related Mortality in HIV/HCV Co-Infected Patients (Poster 1027)
Coverage by Luis Balart, M.D.
Early Prediction of Response to 40 kda Peginterferon alfa-2A (Pegasys) Plus Ribavirin in Patients with Chronic Hepatitis C (Abstract 716)
Coverage by Luis Balart, M.D.

Return to The Body's coverage of
The 52nd Annual Meeting of the American Association for the Study of Liver Diseases.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.